DRKS00015537已完成不适用
Efficacy and safety of Tocilizumab in systemic sclerosis patients: the EUSTAR Database analysis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 98
研究概览
简要总结
No significant effectiveness of tocilizumab was shown in this broader, multicentre, propensity score matched, controlled observational, heterogeneous, non-enriched, real-life SSc population from the large European Scleroderma Trial and Research registry. - The consistency of direction in all predefined primary and secondary endpoints generates hypothesis for potential effectiveness in a broader SSc population rather than in highly selective RCT.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 17 Years 至 one（—）
- 性别
- All
入选标准
- •Age greater or equal 17 years
- •- Observations of patients entering the database after 1.1.2010
- •- Classification criteria for SSc fulfilled (ACR 1980 criteria or 2013 ACR/EULAR criteria)
- •- Potential control patients with disease duration less or equal 35 years
排除标准
- •Not signed or withdrawn informed consent for EUSTAR database
研究者
相似试验
终止
不适用
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic ArthritisArthritis, Juvenile RheumatoidStill's Disease, Juvenile OnsetNCT00868751Tufts Medical Center1
已完成
2 期
Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19COVID-19 disease.COVID-19, virus not identifiedU07.2IRCT20081027001411N4Tehran University of Medical Sciences40
已完成
不适用
The efficacy and safety of tocilizumab in patients with neuromyelitis opticaneuromyelitis opticaJPRN-UMIN000022201Department of Neurology, Shimane University Hospital3
尚未招募
不适用
Role of Tocilizumab in COVID-19 Pneumonia patientsCTRI/2020/08/027246GCS Medical College Hospital and Research Centre
已完成
不适用
Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)Orbitopathy, GravesOphthalmopathyThyroid Eye DiseaseNCT06367517Medical University of Warsaw32